Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Man auctioning comic book collection to pay for cancer treatmenton August 16, 2019 at 8:42 pm
PHOENIX (KNXV/CNN) – Robert Letscher spent most of his life collecting comic books. Now he’s selling off his prized possessions to cover growing medical costs. Letscher is fighting for his life after ...
- UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvion August 16, 2019 at 7:02 pm
Aug 16 (Reuters) - Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly ...
- Ariz. man auctioning comic book collection to pay for cancer treatmenton August 16, 2019 at 5:44 pm
PHOENIX (KNXV/CNN) – Robert Letscher spent most of his life collecting comic books. Now he’s selling off his prized possessions to cover growing medical costs. An Arizona man is auctioning his prized ...
- Mt. Juliet woman works extra shifts to pay for husband's cancer treatmenton August 16, 2019 at 4:06 pm
With medical bills piling up, a Mt. Juliet woman must work extra shifts to help cover her husband's cancer treatments ...
- Comics Collector of Phoenix, Arizona, Sells Signed X-Men to Pay For Cancer Treatmenton August 16, 2019 at 11:36 am
I have pointed out a number of times in the past that you have never seen a crowdfunding campaign to pay for a comic book creator’s healthcare costs from Britain. It’s generally from America. And ...
- Man sells comic collection to pay for cancer treatmenton August 16, 2019 at 10:08 am
Phoenix, AZ (KNXV) — It’s been a passion of his for more than 50 years, and one he didn’t think he’d have to part with so soon. “For some, it kind of makes you a hoarder, but for others ...
- Thyroid cancer worry remains after treatmenton August 16, 2019 at 10:07 am
More than half of a cohort of adults with thyroid cancer identified disease recurrence, quality-of-life deterioration and familial risk as areas of concern following diagnosis, according to findings ...
- Roche personalized cancer treatment to cost about $204,560 a yearon August 16, 2019 at 9:28 am
Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi Aug 16 (Reuters) - Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, ...
- Roche prices personalized cancer treatment at about $204,560 annuallyon August 16, 2019 at 7:56 am
(Reuters) - Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said. The treatment ...
- Could microorganisms in poop help treat the deadliest form of skin cancer?on August 16, 2019 at 7:34 am
Patients will be assessed over time for any changes to their cancer, microbiome, immune system and overall health. The primary goal of the study is to evaluate safety of the novel treatment ...
via Bing News